TB 500 | Thymosin Beta-4

What is TB-500?

TB-500 is a name used for a synthetic peptide associated with thymosin beta-4 research. It should not automatically be treated as identical to full-length recombinant human thymosin beta-4 used in published clinical research. Product identity and supporting analytical documentation matter when interpreting any claim about this compound.

TB-500 5 mg product information

This page does not provide dosage, administration, diagnosis, injury-recovery, or treatment advice.

What does the current research show?

A phase I study in healthy volunteers evaluated recombinant human thymosin beta-4, not this commercial TB-500 vial. Results involving full-length recombinant thymosin beta-4 should not be presented as proof that TB-500 heals injuries, repairs tendons, accelerates muscle recovery, or is safe and effective for human use.

Regulatory context in Canada

Health Canada identifies TB-500 among unauthorized injectable peptide drugs and warns that a “For Research Use Only” label does not remove regulatory requirements. Health Canada advises consumers to use authorized prescription drugs under the care of a licensed health professional and to look for an eight-digit Drug Identification Number (DIN).

Information for tested athletes

The World Anti-Doping Agency Prohibited List names thymosin beta-4 and its derivatives, including TB-500. Athletes subject to anti-doping rules should verify the current list and consult their sport organization or a qualified professional.

Research context matters: evidence level, regulatory status, product identity, and independent documentation should be evaluated separately. No therapeutic or recovery benefit is claimed on this page.

TB-500 5 mg frequently asked questions

How much TB-500 is supplied?

The SRL listing identifies one 5 mg vial. Consult the label and any batch-specific analytical documentation for product details.

Is TB-500 identical to full-length thymosin beta-4?

No identity should be assumed from the name alone. Published studies involving recombinant full-length thymosin beta-4 may not describe the same material as a commercial TB-500 vial.

What biological pathway is associated with thymosin beta-4 research?

The literature describes actin binding and examines cell migration, angiogenesis, inflammatory signalling and tissue-repair models. Those mechanisms do not prove a therapeutic result for this product.

Is TB-500 permitted in tested sport?

WADA names thymosin beta-4 and its derivatives, including TB-500, on the Prohibited List. Athletes should consult the current list and their sport organization.

Does this page provide a recovery protocol?

No. It does not provide dosage, reconstitution, injection or treatment instructions.

What related SRL pages offer additional context?

Compare the BPC-157 research page, the GHK-Cu research page and the complete peptide research category.

Additional scientific references

• Sosne G et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. 2010.
• Thymosin beta4 and actin: binding modes, biological functions and clinical applications. 2023.

Research-use notice: TB-500 5 mg is offered strictly for laboratory research and analytical work. It is not intended for human consumption, self-administration, diagnosis, treatment or veterinary use.